LUCID

Founded in 2021, Canada-based LUCID creates digital therapeutics using ‘Emotion AI’ and music to improve health and wellness. The company’s flagship product, LUC-101, is a digital therapeutic that uses personalized audio to help reduce neuropsychiatric symptoms such as anxiety and agitation in people with Alzheimer’s disease. LUCID's platform also allows users to create their own music-based interventions for various mental health conditions, such as depression, stress, and insomnia.

The company is also developing digital therapeutics for pediatric stress, Alzheimer’s and Dementia, burnout, Parkinson’s, tinnitus, depression, and pain. As of January 2024, LUCID was yet to release LUC-101 for general use.

Key customers and partnerships

In June 2022, LUCID partnered with deep-learning institute Mila to advance machine learning in therapeutic music. Through this partnership, Mila engaged in machine learning research conducted at LUCID.

Prior to this, LUCID partnered with Japanese pharmaceutical company JT in June 2022 to develop personalized music treatment for Alzheimer’s disease. As part of the partnership, JT supported LUCID by translating its data-driven clinical insights into the development of a digital therapeutic to reduce agitation and anxiety in dementia care, initially with Alzheimer’s.

LUCID had also partnered with MINDCURE in April 2021 to discover and create proprietary music experiences for use during psychedelic-assisted therapy sessions. Through this partnership, the companies collaborated to create custom psychedelic music experiences for iSTRYM, MINDCURE’s psychedelics digital therapeutics platform.